Argenx, NL0010832176

argenx stock: Piper Sandler lifts target to 1,350 US dollars

Published on 11/21/2026 at 12:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
argenx stock entered the week with a higher Piper Sandler target and an unchanged Overweight rating. The company remains focused on immunology therapies.

Analyst target lifts shape the week

  • Piper Sandler raised its argenx price target while keeping an Overweight rating on November 16.
  • The company markets approved VYVGART and VYVGART Hytrulo immunology therapies.
Argenx, NL0010832176, Illustration mit AI erstellt.

Analyst action was the key company-specific development for argenx during the week of November 16 to 20, 2026. Piper Sandler raised its price target from 1,215 to 1,350 US dollars on November 16 while retaining an Overweight rating, according to Markets Insider.

Higher target, unchanged stance

The move raised the brokerage's valuation framework without changing its positive rating. Markets Insider reported that Piper Sandler was updating its estimates after third-quarter reporting had largely concluded.

The signal adds to the range of analyst views investors are weighing around argenx. The company is advancing an immunology portfolio that includes the approved therapies VYVGART and VYVGART Hytrulo, according to its investor information.

Saturday market context

argenx stock traded at 848.70 euros on Lang & Schwarz at 11:57 CET on Saturday, November 21, 2026.

argenx company facts

  • Company: argenx
  • ISIN: NL0010832176
  • Lang & Schwarz quote: 848.70 euros at 11:57 CET on November 21, 2026
  • Piper Sandler rating: Overweight on November 16, 2026
  • Piper Sandler price target: 1,350 US dollars, raised from 1,215 US dollars

Broader market direction remains relevant for biotechnology shares and can affect how investors assess sector-specific analyst signals. See Current market reports.

More news and analyses on argenx stock.

Disclaimer...
en | NL0010832176 | ARGENX | boerse | 70542328 | bgmi